GlassScriptPhysician profile
Fahad Khan
NPI 1497174494
$6,156.25
in general payments reported to CMS, 2019-2025
36 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.62 · 2022: $859 · 2023: $875 · 2024: $2,059 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,162 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.79 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,379.87 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $972.25 | 2022-2025 | |
| Amgen INC. | $868.75 | 2022-2025 | Uplizna, Enbrel, Otezla |
| Ucb, INC. | $834.86 | 2022-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $436.09 | 2022-2025 | Tremfya, Simponi Aria |
| Novo Nordisk INC | $215.96 | 2021-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $166.61 | 2022-2025 | |
| Genzyme Corporation | $148.63 | 2023-2025 | |
| Glaxosmithkline, LLC. | $143.80 | 2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $120.79 | 2023-2024 | Lupkynis |
| Horizon Therapeutics Plc | $102.45 | 2022-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $88.59 | 2024-2025 | Orencia |
| Otsuka America Pharmaceutical, INC. | $57.72 | 2025 | Jynarque |
| Apellis Pharmaceuticals, INC. | $55.37 | 2025 | Empaveli |
| Mannkind Corporation | $52.01 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $44.75 | 2024-2025 | Opsumit, Uptravi |
| Lilly USA, LLC | $37.92 | 2024 | Taltz |
| Dexcom, INC. | $37.68 | 2022-2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $36.39 | 2022-2023 | Injectafer |
| Corcept Therapeutics | $33.44 | 2024 | Korlym |
| Invivyd INC | $32.46 | 2025 | Pemgarda |
| Teva Pharmaceuticals USA, INC. | $30.09 | 2023-2024 | Truxima, Simlandi |
| Calliditas Therapeutics US INC. | $22.06 | 2024 | |
| Exact Sciences Corporation | $21.27 | 2024 | Cologuard Collection Kit |
| Amphastar Pharmaceuticals, INC. | $20.99 | 2025 | |
| Insulet Corporation | $20.91 | 2023 | Omnipod |
| Tandem Diabetes Care, INC. | $20.75 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Octapharma USA, INC. | $20.55 | 2025 | Octagam Immune Globulin (Human) |
| Kyowa Kirin, INC. | $19.39 | 2025 | |
| Organon LLC | $18.43 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.22 | 2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $16.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.48 | 2024 | |
| Ani Pharmaceuticals, INC. | $16.04 | 2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $14.30 | 2025 | Amvuttra |
| Recordati_rare_diseases_inc. | $13.86 | 2023 | Isturisa, Signifor Lar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.